An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Matthew S Davids, Peter Hillmen, Marco Montillo, Julio Delgado, Bryone J Kuss, Constantine S Tam, Ulrich Jager, Paolo Ghia, Stephan Stilgenbauer, Florence Cymbalista, Stephanie Lustgarten, David T Weaver, Hagop Youssoufian, Ian W Flinn